Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

PHASE4CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
DRUG

Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)

10 mg and/or 20 mg capsules

DRUG

Placebo

Placebo Comparator

Trial Locations (8)

33143

Miami Research Associates, South Miami

34208

Florida Clinical Research Center, LLC, Bradenton

66212

Vince and Associates Clinical Research, Overland Park

72205

Clinical Study Center, LLC, Little Rock

77007

Bayou City Research, Houston

77008

Claghorn-Lesem Research Clinic, Houston

79423

Behavioral Neurology, Lubbock

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY